Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024050 | 0.94 | HPGD (0.62) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL14371962 | 0.87 | ALDH1A1 (0.65) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL24150763 | 0.86 | ALDH1A1 (0.60) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL3505447 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HPGDLMNAGRM5CTSA | |
| Hydrochloric Acid SCHEMBL10707808 | 0.83 | ALDH1A1 (0.60) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL10707099 | 0.82 | P2RX7 (0.65) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL24742211 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL10711134 | 0.81 | LMNA (0.54) | ALDH1A1HPGDLMNACTSAKMT2A | |
| SCHEMBL10710858 | 0.80 | CTSA (0.53) | ALDH1A1HPGDLMNACTSAKMT2A | |
| SCHEMBL6931 | 0.80 | ALDH1A1 (0.57) | ALDH1A1HPGDLMNAGRM5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| US-20190345143-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2019-11-14 | — | — | US | disclosed |
| EP-3555071-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018107201-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2018-06-21 | — | — | WO | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345143-A1 | HEPARANASE INHIBITORS AND USE THEREOF | HPSE, HEXD, ENGASE | ALDH1A1 1394/4885HPGD 246/4885LMNA 2952/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | ALDH1A1 1394/4885HPGD 246/4885LMNA 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.